



Vascular endothelial growth factor signaling regulates the segregation of artery and vein via ERK activity during vascular development

Se-Hee Kim^{a,1}, Christopher E. Schmitt^{a,b,1}, Melissa J. Woolls^{a,b,1}, Melinda B. Holland^a, Jun-Dae Kim^b, Suk-Won Jin^{b,*}

^a McAllister Heart Institute, Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

^b Yale Cardiovascular Research Center and Section of Cardiovascular Medicine, Dept. of Internal Medicine, Yale University School of Medicine, New Haven, CT 06511, USA

ARTICLE INFO

Article history:

Received 29 November 2012

Available online 22 December 2012

Keywords:

Vascular development

Zebrafish

Vegf-A

Erk

Axial vessel

ABSTRACT

Segregation of two axial vessels, the dorsal aorta and caudal vein, is one of the earliest patterning events occur during development of vasculature. Despite the importance of this process and recent advances in our understanding on vascular patterning during development, molecular mechanisms that coordinate the segregation of axial vessels remain largely elusive. In this report, we find that vascular endothelial growth factor-A (Vegf-A) signaling regulates the segregation of dorsal aorta and axial vein during development. Inhibition of Vegf-A pathway components including ligand Vegf-A and its cognate receptor Kdr1, caused failure in segregation of axial vessels in zebrafish embryos. Similarly, chemical inhibition of Mitogen-activated protein kinase kinase (Map2k1)/Extracellular-signal-regulated kinases (Erk) and phosphatidylinositol 3-kinases (PI3 K), which are downstream effectors of Vegf-A signaling pathway, led to the fusion of two axial vessels. Moreover, we find that restoring Erk activity by over-expression of constitutively active MEK in embryos with a reduced level of Vegf-A signaling can rescue the defects in axial vessel segregation. Taken together, our data show that segregation of axial vessels requires the function of Vegf-A signaling, and Erk may function as the major downstream effector in this process.

© 2012 Elsevier Inc. All rights reserved.

1. Introduction

The vascular network, which provides the essential functions of delivering oxygen and removing metabolic waste products, is one of the first organs to emerge in embryos. In vertebrates, the vascular system is formed by two distinct processes, vasculogenesis, *de novo* formation of blood vessels, and angiogenesis, the formation of new blood vessels from preexisting vessels. During development, endothelial cells, the innermost lining of the vascular network, form transient aggregates known as the vascular cord in the midline [1,2]. Endothelial cells within the vascular cord start to express arterial and venous specific markers as early as E11.5 in mouse [3], and as early as 18 hours post-fertilization (hpf) in zebrafish [1,4], preceding the emergence of morphologically distinct arteries and veins [5].

Subsequently, developing vasculature acquires the stereotypic hierarchy; arteries and veins are physically separated and only connected by the capillaries. Failure to segregate arteries and veins results in ectopic shunts connecting these two types of vessels, a pathological condition known as arteriovenous malformation (AVM) [6]. While the etiology of AVM remains largely unknown, re-

cent advances start to unravel the molecular and cellular mechanisms that underlie the sorting of arterial and venous endothelial cells. Attenuation of several genes has shown to cause failure in segregation of axial vessels in vertebrates. For instance, mutation in *Dll4* in mice causes improper segregation of the dorsal aorta and the cardinal vein, creating arteriovenous shunts [7,8]. Similarly, simultaneous reduction of *sox7* and *sox18* genes resulted in improper segregation of the dorsal aorta and the cardinal vein [9–11]. In all cases, both differentiation of arterial/venous endothelial cells and the segregation of the axial vessels were affected, suggesting that these two events are tightly linked developmental processes.

Recent studies have shown that arterial and venous endothelial cells respond differently to various signaling molecules, which might be the main driving force for the segregation of arteries and veins during development. For instance, vascular endothelial growth factor-A (Vegf-A) and vascular endothelial growth factor-C (Vegf-C) signaling preferentially activates dorsal migration of arterial endothelial cells and ventral migration of venous endothelial cells respectively, within the vascular cord, therefore, synergistically promoting the segregation of axial vessels in zebrafish embryos [2]. In addition, the repulsive interaction between EphrinB2 and EphB4 has been shown to be critical in regulating the segregation of arterial endothelial cells from the venous endothelial cells in developing mouse embryo. The dorsal aorta in mice lacking EphrinB2 or EphB4 contained venous endothelial cells,

* Corresponding author.

E-mail address: suk-won.jin@yale.edu (S.-W. Jin).

¹ These authors contributed equally to this work.

leading to the enlarged dorsal aorta at the expense of the cardinal vein [12]. Later in development, we have recently demonstrated that arterial and venous endothelial cells exhibit different responses to Vegf-A and Bone Morphogenetic Protein (Bmp) signaling [13]. While Bmp signaling induces angiogenesis within venous endothelial cells, arterial endothelial cells remain unaffected. Conversely, Vegf-A signaling preferentially facilitates angiogenesis within arterial endothelial cells without activating venous endothelial cells. Collectively, these reports indicate distinct molecular nature of arterial and venous endothelial cells. However, it is unclear how differences in molecular characteristics of arterial and venous endothelial cells contribute to the segregation of axial vessels. Moreover, it is unknown which signaling pathways regulate the segregation of axial vessels during development. Considering its importance during vascular development, it is likely that VEGF-A signaling may provide a pivotal function in this process.

In this study, we used zebrafish as a model system to investigate the role of Vegf-A signaling during the segregation of axial vessels. We find that reduction in Vegf-A signaling activity led to a failure in the segregation of arteries and veins. Moreover, we find that inhibition of Erk, which are known to function downstream of Vegf-A signaling pathway [4] yield similar defects in developing zebrafish, while activation of Erk in embryos with a reduced level of Vegf-A activity can restore the segregation defects, indicating that activation of Erk by Vegf-A signaling is essential for the proper segregation of axial vessels. Taken together, our data demonstrate the critical role of Vegf-A signaling during the segregation of axial vessels.

2. Methods and materials

2.1. Zebrafish husbandry and positional cloning

Zebrafish (*Danio rerio*) embryos and adults were raised and maintained as previously described under IACUC guidelines [14].

2.2. Microinjection and chemical treatment

Morpholinos (MO) (Gene Tools, LLC) were injected into 1-cell-stage *Tg(kdrl:EGFP)* embryos as previously described [1]. The sequences of MOs used in this study are; *kdrl*: 5'-CACAAAAGCGC ACATTACCATGT-3', *vegfa*: 5'-CTCGTCTTATTCCTGACTGTTT-3' [15], *kdrl*: 5'-GTTTTCTTGATCTCACCTGAACCT-3', *ephrinb2a*: 5'-CGGTCAAATTCGTTTCGCGGA-3' [16], *plcy*: 5'-ATTAGCATAGGGA AACTTACTTTCG-3' [17]. For chemical treatment, embryos were treated from the 10 somite stage to 30 h post fertilization (hpf) unless noted otherwise, and fixed overnight in 4% paraformaldehyde (PFA). To transiently express constitutively active MEK (CA-MEK) [18] in endothelial cells, CA-MEK was subcloned into the Gateway middle entry vector and recombined into *kdrl* promoter containing vector. The resulting construct allows *kdrl* promoter regulated, transient expression of CA-MEK in a subset of endothelial cells in injected embryos.

2.3. Immunohistochemistry, western blot, and in situ hybridization

Immunohistochemistry and *in situ* hybridization were performed as previously described [1]. Anti- β -catenin antibody (1:150, BD Biosciences) was used to show cell boundaries.

2.4. Phenotypic analyses

30 hpf zebrafish embryos were analyzed by fluorescent stereomicroscope to examine the vascular morphology. For those appear

to contain a single axial vessels, transverse sections from 10th somite to 18th somite of 30 hpf zebrafish embryos were analyzed by confocal microscopy. Minimum of ten sections per embryos were analyzed. If the embryo had more than seven sections with single axial vessels, it was counted as 'embryos with a single axial vessel'.

2.5. Quantitative RT-PCR

Quantitative RT-PCR was performed as previously reported [19]. The trunk region (above the yolk extension) of the embryos was dissected and RNA was extracted, and pre-tested qRT-PCR primers (Applied biosystems) were used to detect the gene expression.

3. Results and discussion

To examine the function of Vegf-A signaling during segregation of axial vessels, we attenuated the function of well characterized components of Vegf-A signaling in *Tg(kdrl:EGFP)^{s843}* embryos [1]. Blocking Vegf-A signaling by injecting morpholino (MO) against *vegfa* or *plcy* caused failure in segregation of axial vessels (Fig. 1A–C), indicating that Vegf-A signaling plays an important role in the segregation of axial vessels.

In zebrafish genome, two functional orthologs of vascular endothelial growth factor receptor 2 (VEGFR2/KDR), *vegfr2/kdr* and *vegfr4/kdrl* are present [20]. Previously, it has been shown that the function of Kdr appears to be largely dispensable for the




Fig. 1. Attenuation of Vegf-A signaling components causes defects in axial vessel segregation as observed in *kdrl^{s828}* mutants. Transverse sections taken at the level of the 14th somite were analyzed by confocal microscopy. 36 hpf wild-type (A), *vegfa* MO injected (B), and *plcy* MO injected (C) embryos in *Tg(kdrl:EGFP)^{s843}* background. Endothelial cells are visualized by the expression of EGFP transgene (green), cell boundaries are shown by Anti- β -catenin staining (red). White arrows in panels B and C point to the single axial vessel. Abbreviations: DA, dorsal aorta, CV, caudal vein. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)




Fig. 2. Kdr1 functions as the main receptor for Vegf-A signaling during the segregation of axial vessels. Bright field micrographs (top row), epifluorescence micrographs (middle row), and confocal images of a transverse section at the 14th somite level (bottom row) of 36 hpf embryos injected with control MO (A), *kdr1* MO (B), or *kdr* MO (C) in *Tg(kdr1:EGFP)⁸⁴³* background. Endothelial cells are visualized by the expression of EGFP transgene (green), cell boundaries are shown by Anti- β -catenin staining (red). White arrowhead in panel B points to the single axial vessel. (D) Quantitative RT-PCR of endothelial specific genes in 36 hpf MO injected embryos. Attenuation of either *kdr1* or *kdr* significantly reduced the expression of arterial and venous marker expression. Abbreviations: DA, dorsal aorta, CV, caudal vein. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

specification of arterial endothelial cells, although Kdr1 and Kdr might function redundantly to promote segmental artery formation [21]. Therefore, it is plausible that Kdr1 and Kdr may have a distinct role in transducing the activity of Vegf-A signaling during axial vessel segregation in zebrafish. To examine this possibility, we selectively inhibited Kdr1 or Kdr during development, and analyze the resulting vascular phenotype (Fig. 2).

While embryos injected with *kdr1* MO contained only a single axial vessel, those injected with *kdr* MO injected embryos had a distinct dorsal aorta and axial vein, suggesting that the function of Kdr may be dispensable for the segregation of axial vessels (Fig. 2B and C). Furthermore, the severity and penetrance of defects on axial vessel segregation in embryos co-injected with *kdr1* and *kdr* MO were comparable to those of embryos injected with *kdr1* MO alone, suggesting that the contribution of Kdr to the segregation of axial vessels is likely to be minor.

Interestingly, blocking either Kdr1 or Kdr function led a significant reduction in the expression level of arterial and venous specific genes, indicating that both Vegfr2/KDR orthologs are required to promote or maintain the expression of differentiated endothelial cell markers (Fig. 2D). Taken together, it seems that both Kdr and Kdr1 are required to maintain and/or initiate differentiation of endothelial cells, while Kdr1 appears to be the main Vegf-A receptor during segregation of axial vessels.

One of the main downstream effector of Vegf-A signaling is Protein Kinase C (PKC), which is activated by diacylglycerol (DAG) [22]. It has been shown that inhibition of PKC by chemical antagonists blocks the pro-angiogenic effects of Vegf-A signaling. To test

whether PKC is also involved in transducing Vegf-A signaling during segregation of axial vessels, we attenuated the level of PKC activity. 14 hpf wild-type zebrafish embryos were treated with 60 μ M bisindolylmaleimide, a known antagonist of PKC, for 16 h [23]. As a positive control, SU5416, a well characterized chemical antagonist of VEGFR2, was used. In embryos treated with SU5416, the axial vessels failed to segregate as expected ($n = 20$) (Fig. 3A and E). Similarly, we find that failure in segregation of axial vessels failed in embryos with reduced PKC activity ($n = 75$) (Fig. 3B and E), indicating that PKC is an essential mediator for Vegf-A signaling during segregation of axial vessels.

Two prominent downstream effectors of PKC activity in the Vegf-A signaling cascade is Map2k1/Erk and Akt/PI3 K, which elicit a variety of cellular responses including increased vascular permeability, elevated eNOS production, and initiation of Vegf-A target genes [24]. To determine the function of these two signaling pathways in transducing Vegf-A signaling during the segregation of axial vessels, we also attenuated the activity of Map2k1/Erk or Akt/PI3 K, and examined the resulting vascular phenotype.

When embryos were treated with 25 M U0126, a chemical antagonist of Map2k1/Erk [25], from 14 to 30 hpf, a significant portion of the embryos had a single axial vessel with impaired circulation, which was reminiscent of the phenotype of embryos with compromised Vegf-A signaling ($n = 105$), suggesting that the Map2k1/Erk activity is required to mediate Vegf-A signaling during the segregation of axial vessels (Fig. 3C and E).

Similarly, to investigate the contribution of Akt/PI3 K in antagonizes Map2k1/Erk in a similar manner to modulate Vegf-A signal-




Fig. 3. Attenuation of Vegf-A downstream effectors caused defects in segregation of axial vessels. Transverse sections taken at the level of the 14th somite were analyzed by confocal microscopy. 36 hpf *Tg(kdr:EGFP)⁸⁴³* embryos treated with 1 μ M SU5416 (A), 60 μ M Bisindolylmaleimide, a chemical antagonist of PKC (B), 25 M U0126 (C), or 30 μ M LY294002 (D). (E) Quantification of chemical treatments. Compared to DMSO treated embryos, the percentage of embryos with a single axial vessel was significantly increased in embryos treated with SU5416, Bisindolylmaleimide, U0126, or LY294002 ($P < 0.001$).




Fig. 4. Activation of PKC or Erk activity can rescue the defects in segregation of axial vessels in embryos with compromised Vegf-A signaling. Transverse sections taken at the level of the 14th somite were analyzed by confocal microscopy. 36 hpf *Tg(kdr:EGFP)⁸⁴³* embryos treated with DMSO (left), 7.5 μ g/ml GS4012 (middle), and 16 μ M 12-O-tetradecanoylphorbol-13-acetate (right). (B) Treatment with 16 μ M 12-O-tetradecanoylphorbol-13-acetate restored the defects in segregation of axial vessels better than GS4012, a positive control. (C) Transverse sections taken at the level of the 14th somite from *kdr* MO injected embryos, co-injected with either vector containing Blue Fluorescent Protein (BFP) or constitutively active MEK (CA-MEK). (D) PCR confirmation showing the validity of *kdr* MO (left) and expression of CA-MEK construct (right). (E) The defect in axial vessel segregation in *kdr* MO injected embryos was substantially rescued by ectopic activation of MEK, which can increase the level of Erk activity. Abbreviations: DA, dorsal aorta, CV, caudal vein. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

ing during the segregation of axial vessels, we treated embryos from 14 to 30 hpf with 30 M LY294002, a chemical antagonist that inhibits phosphorylation of Akt therefore attenuating PI3 K activity

($n = 98$) [26]. Inhibition of PI3 K activity at this stage caused vascular defects comparable to Map2k1/Erk inhibition (Fig. 3D and E). Approximately 70 percent of the embryos treated with LY294002

displayed a single axial vessel (Fig. 3E). Taken together, our data indicate that effects of Vegf-A signaling during the segregation of the axial vessels require the activity of PKC, Erk, and PI3 K.

To examine whether activation of these downstream effectors is sufficient to initiate segregation of axial vessels in embryos with a reduced level of Vegf-A signaling, we utilized chemical genetics approach. To test whether the activation of PKC is sufficient to bypass the requirement of Vegf-A signaling, *kdrl* MO injected embryos were incubated with 16 μ M 12-O-tetradecanoylphorbol-13-acetate (TPA) [27], a chemical agonist of PKC from 14 to 30 hpf. As a positive control, we used GS4012, a chemical agonist of Vegf-A signaling. While *kdrl* MO injected embryos incubated with DMSO (empty vehicle) contained a single axial vessel ($n = 40$, Fig. 4A and B), 77 percent of *kdrl* MO injected embryos treated with GS4012, and 86 percent of *kdrl* MO injected embryos incubated with TPA had a clearly separate dorsal aorta and axial vein ($n = 55$ for GS4012, and $n = 42$ for TPA, Fig. 4A and B). Therefore, activation of PKC is sufficient to alleviate defects on the segregation of axial vessels caused by reduced Vegf-A signaling.

To further examine the function of Map2k1/Erk in the segregation of axial vessels, constitutively active MEK (CA-MEK) was selectively expressed in endothelial cells in *kdrl* MO injected embryos [18] (Fig. 4C and D). Since MEK induces activation of Map2k1/Erk, ectopic expression of CA-MEK in endothelial cells should alleviate the phenotype of *kdrl* MO injected embryos. While less than two percent of embryos co-injected with a vector encoding Blue Fluorescent Protein (BFP) and *kdrl* MO contained two axial vessels at 28 hpf (Fig. 4E), a significant portion (38%) of embryos co-injected with the CA-MEK construct and *kdrl* MO had clearly distinguishable axial vessels (Fig. 4E), suggesting that Map2k1/Erk activity is critical for the segregation of the axial vessels, but dispensable for the maintenance of the arterial or venous specific gene expression downstream of Vegfr signaling.

4. Conclusion

In this report, we investigated the function of Vegf-A signaling in the segregation of axial vessels during vertebrate development. We find that Vegf-A signaling is indispensable for the proper segregation of axial vessels. Among two zebrafish orthologs of VEGFR2/KDR, we find that the function of Kdr appears to be dispensable for the segregation of axial vessels. Despite drastically reduced expression of arterial or venous markers, a distinct dorsal aorta and axial vein were formed in *kdrl* MO injected embryos. Therefore, it appears that Kdr is the main receptor to mediate Vegf-A signaling during the segregation of axial vessels. During the segregation of axial vessels, Vegf-A signaling appears to promote activity of Erk and PI3 K, since inhibition of either Erk or PI3 K activity caused similar vascular defects as in embryos with compromised Vegf-A signaling. Moreover, activation of Erk signaling in Vegf-A signaling deficient embryos restored the defects in axial vessel segregation, indicating that Erk signaling may play a key role in mediating Vegf-A signaling activity in this process.

Acknowledgments

The authors would like to thank members of Jin lab for helpful discussion. This work has been supported by Developmental Biology Training Grant to C.E.S. and American Heart Association Pre-doctoral Fellowship to M.J.W., American Heart Association Pre-doctoral Fellowship to J.D.K., and Grants from the NIH (HL090960) and the American Heart Association Scientist Development Award to S.-W.J.

References

- [1] S.W. Jin, D. Beis, T. Mitchell, J.N. Chen, D.Y. Stainier, Cellular and molecular analyses of vascular tube and lumen formation in zebrafish, *Development* 132 (2005) 5199–5209.
- [2] S.P. Herbert, J. Huisken, T.N. Kim, M.E. Feldman, B.T. Houseman, R.A. Wang, K.M. Shokat, D.Y. Stainier, Arterial-venous segregation by selective cell sprouting: an alternative mode of blood vessel formation, *Science* 326 (2009) 294–298.
- [3] R.H. Adams, G.A. Wilkinson, C. Weiss, F. Diella, N.W. Gale, U. Deutsch, W. Risau, R. Klein, Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis, *Genes Dev.* 13 (1999) 295–306.
- [4] C.C. Hong, Q.P. Peterson, J.Y. Hong, R.T. Peterson, Artery/vein specification is governed by opposing phosphatidylinositol-3 kinase and MAP kinase/ERK signaling, *Curr. Biol.* 16 (2006) 1366–1372.
- [5] S.W. Jin, C. Patterson, The opening act: vasculogenesis and the origins of circulation, *Arterioscler., Thromb., Vasc. Biol.* 29 (2009) 623–629.
- [6] G.G. Leblanc, E. Golanov, I.A. Awad, W.L. Young, Biology of vascular malformations of the brain, *Stroke* 40 (2009) e694–e702.
- [7] A. Duarte, M. Hirashima, R. Benedito, A. Trindade, P. Diniz, E. Bekman, L. Costa, D. Henrique, J. Rossant, Dosage-sensitive requirement for mouse Dll4 in artery development, *Genes Dev.* 18 (2004) 2474–2478.
- [8] N.W. Gale, M.G. Dominguez, I. Noguera, L. Pan, V. Hughes, D.M. Valenzuela, A.J. Murphy, N.C. Adams, H.C. Lin, J. Holash, G. Thurston, G.D. Yancopoulos, Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development, *Proc. Natl. Acad. Sci. USA* 101 (2004) 15949–15954.
- [9] H. Pendevel, M. Winandy, I. Manfroid, O. Nivelles, P. Motte, V. Pasque, B. Peers, I. Struman, J.A. Martial, M.L. Voz, Zebrafish Sox7 and Sox18 function together to control arterial-venous identity, *Dev. Biol.* 317 (2008) 405–416.
- [10] R. Herpers, E. van de Kamp, H.J. Duckers, S. Schulte-Merker, Redundant roles for Sox7 and Sox18 in arteriovenous specification in zebrafish, *Circ. Res.* 102 (2008) 12–15.
- [11] S. Cermenati, S. Molero, S. Cimbri, P. Corti, L. Del Giacco, R. Amodeo, E. Dejana, P. Koopman, F. Cotelli, M. Beltrame, Sox18 and Sox7 play redundant roles in vascular development, *Blood* 111 (2008) 2657–2666.
- [12] Y.H. Kim, H. Hu, S. Guevara-Gallardo, M.T. Lam, S.Y. Fong, R.A. Wang, Artery and vein size is balanced by Notch and ephrin B2/EphB4 during angiogenesis, *Development* 135 (2008) 3755–3764.
- [13] D.M. Wiley, J.D. Kim, J. Hao, C.C. Hong, V.L. Bautsch, S.W. Jin, Distinct signaling pathways regulate sprouting angiogenesis from the dorsal aorta and axial vein, *Nat. Cell Biol.* 13 (6) (2011) 686–692.
- [14] M. Westerfield, *The Zebrafish Book, A Guide for the Laboratory Use of Zebrafish (Danio Rerio)*, Fourth ed., University of Oregon Press, Eugene, 2000.
- [15] A. Nasevicius, S.C. Ekker, Effective targeted gene ‘knockdown’ in zebrafish, *Nat. Genet.* 26 (2000) 216–220.
- [16] J.E. Cooke, H.A. Kemp, C.B. Moens, EphA4 is required for cell adhesion and rhombomere-boundary formation in the zebrafish, *Curr. Biol.* 15 (2005) 536–542.
- [17] N.D. Lawson, J.W. Mugford, B.A. Diamond, B.M. Weinstein, Phospholipase C gamma-1 is required downstream of vascular endothelial growth factor during arterial development, *Genes Dev.* 17 (2003) 1346–1351.
- [18] F.A. Scholl, P.A. Dumesic, P.A. Khavari, Mek1 alters epidermal growth and differentiation, *Cancer Res.* 64 (2004) 6035–6040.
- [19] C.Y. Lee, K.M. Vogeli, S.H. Kim, S.W. Chong, Y.J. Jiang, D.Y. Stainier, S.W. Jin, Notch signaling functions as a cell-fate switch between the endothelial and hematopoietic lineages, *Curr. Biol.* 19 (2009) 1616–1622.
- [20] J. Bussmann, N. Lawson, L. Zon, S. Schulte-Merker, Zebrafish VEGF receptors: a guideline to nomenclature, *PLoS Genet.* 4 (2008) e1000064.
- [21] L.D. Covassin, J.A. Villefranc, M.C. Kacergis, B.M. Weinstein, N.D. Lawson, Distinct genetic interactions between multiple VEGF receptors are required for development of different blood vessel types in zebrafish, *Proc. Natl. Acad. Sci. USA* 103 (2006) 6554–6559.
- [22] C.C. Hong, T. Kume, R.T. Peterson, Role of crosstalk between phosphatidylinositol 3-kinase and extracellular signal-regulated kinase/mitogen-activated protein kinase pathways in artery-vein specification, *Circ. Res.* 103 (2008) 573–579.
- [23] D. Toullec, P. Pianetti, H. Coste, P. Bellevergue, T. Grand-Perret, M. Ajakane, V. Baudet, P. Boissin, E. Boursier, F. Loriolle, et al., The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C, *J. Biol. Chem.* 266 (1991) 15771–15781.
- [24] I. Zachary, VEGF signalling: integration and multi-tasking in endothelial cell biology, *Biochem. Soc. Trans.* 31 (2003) 1171–1177.
- [25] M.F. Favata, K.Y. Horiuchi, E.J. Manos, A.J. Daulerio, D.A. Stradley, W.S. Feeser, D.E. Van Dyk, W.J. Pitts, R.A. Earl, F. Hobbs, R.A. Copeland, R.L. Magolda, P.A. Scherle, J.M. Trzaskos, Identification of a novel inhibitor of mitogen-activated protein kinase kinase, *J. Biol. Chem.* 273 (1998) 18623–18632.
- [26] C.J. Vlahos, W.F. Matter, K.Y. Hui, R.F. Brown, A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002), *J. Biol. Chem.* 269 (1994) 5241–5248.
- [27] R.M. Bell, Y.A. Hannun, C.R. Loomis, Mechanism of regulation of protein kinase C by lipid second messengers, *Symp. Fundam. Cancer Res.* 39 (1986) 145–156.